Researchers analyzed data from nearly 4,000 pediatric patients to compare different topical treatments for atopic dermatitis. The study looked at several nonsteroidal options, including delgocitinib, difamilast, and tapinarof, to see how they performed compared to a standard vehicle treatment.
The findings showed that most active treatments improved skin condition scores over the vehicle. Specifically, delgocitinib ranked highest for one measure of success, while difamilast ranked highest for another. While five out of ten regimens showed significant benefits in reducing eczema area, all six regimens tested for a high level of improvement were superior to the vehicle.
These treatments are considered promising because they do not contain steroids. However, this study was a network meta-analysis with limited direct comparisons between the active drugs themselves. Because long-term data is missing and evidence for specific age groups is limited, these findings should be viewed as an early look at short-term options. Talk to a doctor to see if these treatments are right for your child.
